An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib

International Journal of Laboratory Hematology

Volumn 33, Issue 2, 2011, Pages 176-181

  Xing, H ^a,b   Liu, T ^a   Meng, W ^c   Gong, Y ^a  

^a SICHUAN UNIVERSITY   (China)

^b SOUTHWEST MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Bortezomib; Dasatinib; Imatinib resistance; Nilotinib; Rapamycin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BCR ABL PROTEIN; BORTEZOMIB; DASATINIB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMATINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NILOTINIB; PROTEASOME; RAPAMYCIN; S6 KINASE; UBIQUITIN;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; PIPERAZINES; PYRAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; SIROLIMUS; THIAZOLES; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 79952474487     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2010.01267.x     Document Type: Article

References (26)

1. Bartram C.R., de Klein A., Hagemeijer A., van Agthoven T., Geurts van Kessel A., Bootsma D., Grosveld G., Ferguson-Smith M.A., Davies T. & Stone M. (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306, 277-280.
2. von Bubnoff N., Peschel C. & Duyster J. (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib(STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17, 829-838.
3. Cortes J., Thomas D., Koller C., Giles F., Estey E., Faderl S., Garcia-Manero G., McConkey D., Ruiz S.L., Guerciolini R., Wright J. & Kantarjian H. (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clinical Cancer Research 10, 3371-3776.
4. Deininger M., Buchdunger E. & Druker B.J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653.
5. Goldman J.M. & Melo J.V. (2003) Chronic myeloid leukemia - advances in biology and new approaches to treatment. New England Journal of Medicine 349, 1451-1464.
6. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N. & Sawyers C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
7. Hirase C., Maeda Y., Takai S. & Kanamaru A. (2008) Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leukemia Research. 33, 450-459.
8. Hu Z., Pan X.F., Wu F.Q., Ma L.Y., Liu D.P., Liu Y., Feng T.T., Meng F.Y., Liu X.L., Jiang Q.L., Chen X.Q., Liu J.L., Liu P., Chen Z., Chen S.J. & Zhou G.B. (2009) Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS ONE 4, e6257.
9. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J.D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L. & Ottmann O.G. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine 354, 2542-2551.
10. Kharas M.G., Janes M.R., Scarfone V.M., Lilly M.B., Knight Z.A., Shokat K.M. & Fruman D.A. (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. Journal of Clinical Investigation 118, 3038-3050.
11. Kim J.H., Chu S.C., Gramlich J.L., Pride Y.B., Babendreier E., Chauhan D., Salgia R., Podar K., Griffin J.D. & Sattler M. (2005) Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 105, 1717-1723.
12. de Klein A., van Kessel A.G., Grosveld G., Bartram C.R., Hagemeijer A., Bootsma D., Spurr N.K., Heisterkamp N., Groffen J. & Stephenson J.R. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767.
13. Legros L., Hayette S., Nicolini F.E., Raynaud S., Chabane K., Magaud J.P., Cassuto J.P. & Michallet M. (2007) BCR-ABL (T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonnine: a new therapeutic challenge? Leukemia 21, 2204-2206.
14. Ly C., Arechiga A.F., Melo J.V., Walsh C.M. & Ong S.T. (2003) Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Research 63, 5716-5722.
15. Mahon F.X., Deininger M.W., Schultheis B., Chabrol J., Reiffers J., Goldman J.M. & Melo J.V. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070-1079.
16. Mayerhofer M., Aichberger K.J., Florian F., Krauth M.T., Hauswirth A.W., Derdak S., Sperr W.R., Esterbauer H., Wagner O., Marosi S., Pickl W.F., Deininger M., Weisberg E., Druker B.J., Griffin J.D., Sillaber C. & Valent P. (2005) Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB Journal 2005, 19.
17. McCloskey S.M., McMullin M.F., Walker B. & Irvine A.E. (2008) The therapeutic potential of the proteasome in leukaemia. Hematological Oncology 26, 73-81.
18. Mohi M.G., Boulton C., Gu T.L., Sternberg D.W., Neuberg D., Griffin J.D., Gilliland D.G. & Neel B.G. (2004) Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proceedings of the National Academy of Sciences of the United States of America 101, 3130-3135.
19. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., Cowan-Jacob S.W., Lee F.Y., Heinrich M.C., Deininger M.W. & Druker B.J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research 65, 4500-4505.
20. Récher C., Beyne-Rauzy O., Demur C., Chicanne G., Dos Santos C., Mas V.M., Benzaquen D., Laurent G., Huguet F. & Payrastre B. (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527-2534.
21. Redaelli S., Piazza R., Rostagno R., Magistroni V., Perini P., Marega M. & Gambacorti-Passerini C&.Boschelli.F. (2009) Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Journal of Clinical Oncology 27, 469-471.
22. Ren R. (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews. Cancer 5, 172-183.
23. Rix U., Hantschel O., Dürnberger G., Remsing Rix L.L., Planyavsky M., Fernbach N.V., Kaupe I., Bennett K.L., Valent P., Colinge J., Köcher T. & Superti-Furga G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110, 4055-4063.
24. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D. & Sawyers C.L. (2004) Overriding imatinib resistance with a novel AB kinase inhibitor. Science 305, 399-401.
25. Sillaber C., Mayerhofer M., Böhm A., Vales A., Gruze A., Aichberger K.J., Esterbauer H., Pfeilstöcker M., Sperr W.R., Pickl W.F., Haas O.A. & Valent P. (2008) Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. European Journal of Clinical Investigation 38, 43-52.
26. Soverini S., Colarossi S., Gnani A., Castagnetti F., Rosti G., Bosi C., Paolini S., Rondoni M., Piccaluga P.P., Palandri F., Giannoulia P., Marzocchi G., Luatti S., Testoni N., Iacobucci I., Cilloni D., Saglio G., Baccarani M. & Martinelli G. (2007) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92, 401-404.